Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04000529
Other study ID # CTNO155B12101
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date July 30, 2019
Est. completion date January 15, 2024

Study information

Verified date January 2024
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors. These two treatment arms enrolled subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity. The study treatment was administered until the subject experienced unacceptable toxicity, progressive disease, and/or had treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent.


Description:

Rationale The purpose of this study was to evaluate the safety, tolerability, and preliminary efficacy of the combination of TNO155 with spartalizumab and of TNO155 with ribociclib, and to identify dosing regimens for further study. Data from preclinical models have demonstrated anti-tumor activity for the combinations of TNO155 with spartalizumab and of TNO155 with ribociclib that is superior to the activity observed with each of the drugs as single agents. These data suggest that these combinations may provide clinical benefit to patients with advanced malignancies. Study Design This study was a Phase Ib, multi-center, open-label study with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors to characterize the safety and tolerability TNO155 in combination with spartalizumab and of TNO155 in combination with ribociclib and to identify the MTD and/or recommended regimen (dose and schedule) for each combination. The study treatment was administered until the subject experienced unacceptable toxicity, progressive disease, and/or had treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent. Objectives Primary objective: To characterize the safety and tolerability TNO155 in combination with spartalizumab and of TNO155 in combination with ribociclib, and to identify the MTD and/or recommended regimen (dose and schedule) for each combination. Secondary objectives: - To characterize the pharmacokinetic (PK) profile of TNO155, spartalizumab and ribociclib when administered as a combination of TNO155 plus spartalizumab or of TNO155 plus ribociclib. - To evaluate the preliminary anti-tumor activity of TNO155 in combination with spartalizumab and of TNO155 in combination with ribociclib.


Recruitment information / eligibility

Status Terminated
Enrollment 122
Est. completion date January 15, 2024
Est. primary completion date January 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Age = 18 years. For Japan only: written consent is necessary both from the patient and his/her legal representative if he/she is under the age of 20 years. 3. ECOG (Eastern Cooperative Oncology Group) performance status = 1. 4. Dose escalation part: Patients with advanced solid tumors, with evaluable disease as determined by RECIST version 1.1, and fit into one of the following groups: a. For TNO155 plus spartalizumab combination: i. Advanced EGFR WT, ALK WT NSCLC, after progression on or intolerance to platinum-containing combination chemotherapy and after progression on anti-PD-1 or anti-PD-L1 therapy. ii. Advanced HNSCC or esophageal SCC, after progression on or intolerance to platinum-containing combination chemotherapy. iii. Advanced CRC, after progression on or intolerance to all standard-of-care (SOC) therapy per local guidelines. b. For TNO155 plus ribociclib combination: Advanced solid malignancies with the exception of CRC or GIST, after progression on or intolerance to all SOC therapy per local guidelines. The exclusion of CRC applies only as of Protocol Amendment 4. 5. Dose expansion part: Patients with advanced solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who fit into one of the following groups: a. For TNO155 plus spartalizumab combination: i. Advanced EGFR WT, ALK WT, KRAS G12C NSCLC after progression on or intolerance to platinum-containing combination chemotherapy and after progression on anti-PD-1 or anti-PD-L1 therapy. ii. Advanced EGFR WT, ALK WT, KRAS WT NSCLC, after progression on or intolerance to platinum-containing combination chemotherapy and after progression on anti-PD-1 or anti-PD-L1 therapy. iii. Advanced HNSCC, after progression on or intolerance to, platinum-containing combination chemotherapy. b. For TNO155 plus ribociclib combination: i. Advanced EGFR WT, ALK WT, KRAS WT NSCLC, after progression on or intolerance to platinum-containing chemotherapy and anti-PD-1 or anti-PD-L1 therapy ii. Advanced HNSCC, after progression on or intolerance to all SOC per local guidelines 6. Patients with NSCLC whose tumors harbor genomic aberrations for which SOC targeted therapies exist and are locally approved and available must have had progression on or after, or intolerance to, the SOC targeted therapy/therapies as indicated 7. Patients must have a site of disease amenable to biopsy Key Exclusion Criteria: 1. Prior treatment with a MAPK pathway inhibitor 2. Clinically significant cardiac disease or risk factors 3. Use of any agent known to prolong the QT interval unless it can be permanently discontinued for the duration of study (see list in Section 6.2.2). 4. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO 5. Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drugs 6. Symptomatic CNS metastases which are neurologically unstable 7. Insufficient bone marrow function at screening: 1. Absolute Neutrophil Count (ANC) < 1.5 x 109/L. 2. Hemoglobin < 9.0 g/dL. 3. Platelets < 75 x 109/L for TNO155 plus spartalizumab combination; < 100 x 109/L for TNO155 plus ribociclib combination. 8. Insufficient hepatic or renal function at screening: 1. Serum total bilirubin > upper limit of normal (ULN) or, for TNO155 plus spartalizumab combination only, if liver metastases are present at baseline, serum total bilirubin > 1.5 x ULN. An exception for either combination is for patients with Gilbert's syndrome, who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN 2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x ULN for TNO155 plus spartalizumab combination or > 2.5 x ULN for TNO155 plus ribociclib combination, or > 5 x ULN for either combination if liver metastases are present. 3. Creatinine clearance < 60 mL/min (calculated using Cockcroft-Gault equation). 9. Pregnant or breast-feeding (lactating) women. Additional exclusion criteria for the TNO155 plus spartalizumab combination 10. History of severe hypersensitivity reactions to other mAbs. 11. Active, known or suspected autoimmune disease. 12. History of or current interstitial lung disease or pneumonitis grade = 2. 13. Human Immunodeficiency Virus (HIV) infection, unless the patient is on antiviral therapy and has undetectable viral load. 14. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. 15. Systemic chronic steroid therapy 16. Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related toxicity. Additional exclusion criteria for the TNO155 plus ribociclib combination 17. Systolic Blood Pressure (SBP) < 90 mmHg. 18. International Normalized Ratio (INR) > 1.5 (unless the patient is receiving anticoagulants and the INR is within the therapeutic range of intended use for that anticoagulant within seven days prior to the first dose of study drug). 19. History of HIV infection (testing not mandatory) 20. Currently receiving any of the following substances and cannot be discontinued seven days prior to Cycle 1 Day 1: - Concomitant medications or herbal supplements, that are strong inducers or inhibitors of CYP3A4/5, - Medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5. 21. Previous treatment with a CDK4/6 inhibitor. 22. Patient is currently receiving or has received systemic corticosteroids = 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment. Note: The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TNO155
Capsule
Spartalizumab
Concentrate for solution for infusion
Ribociclib
Capsule and tablet

Locations

Country Name City State
Australia Novartis Investigative Site Westmead New South Wales
Belgium Novartis Investigative Site Bruxelles
China Novartis Investigative Site Chengdu Sichuan
Germany Novartis Investigative Site Koeln
Hong Kong Novartis Investigative Site Hong Kong
Japan Novartis Investigative Site Chuo ku Tokyo
Singapore Novartis Investigative Site Singapore
Spain Novartis Investigative Site Barcelona Catalunya
Spain Novartis Investigative Site Valencia Comunidad Valenciana
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  China,  Germany,  Hong Kong,  Japan,  Singapore,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary DLT incidence Incidence of dose limiting toxicities (DLTs) during the first cycle of combination treatment during the dose escalation part 1 year
Primary AE and SAE incidence Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as per CTCAE v5.0, by treatment 3 years
Primary Dose interruptions, reductions and dose intensity, by treatment Dose tolerability 3 years
Secondary Pharmacokinetics (PK): Cmax Cmax for TNO155, spartalizumab, and ribociclib 3 years
Secondary Pharmacokinetics (PK): Tmax Tmax for TNO155, spartalizumab, and ribociclib 3 years
Secondary Pharmacokinetics (PK): AUClast AUClast for TNO155, spartalizumab, and ribociclib 3 years
Secondary Pharmacokinetics (PK): AUCtau AUCtau for TNO155, spartalizumab, and ribociclib 3 years
Secondary Efficacy measurements per RECIST v1.1: ORR Overall response rate (ORR) per RECIST v1.1, by treatment 3 years
Secondary Efficacy measurements per RECIST v1.1: DCR Disease control rate (DCR) per RECIST v1.1, by treatment 3 years
Secondary Efficacy measurements per RECIST v1.1: PFS Progression-free survival (PFS) per RECIST v1.1, by treatment 3 years
Secondary Efficacy measurements per RECIST v1.1: DOR Duration of response (DOR) per RECIST v1.1, by treatment 3 years
Secondary Efficacy measurements per iRECIST: ORR Overall response rate (ORR) per iRECIST for TNO155 in combination with spartalizumab 3 years
Secondary Efficacy measurements per iRECIST: DCR Disease control rate (DCR) per iRECIST for TNO155 in combination with spartalizumab 3 years
Secondary Efficacy measurements per iRECIST: PFS Progression-free survival (PFS) per iRECIST for TNO155 in combination with spartalizumab 3 years
Secondary Efficacy measurements per iRECIST: DOR Duration of response (DOR) per iRECIST for TNO155 in combination with spartalizumab 3 years
Secondary Overall Survival Overall survival (OS) by treatment 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A